Latuda: Uses, Side Effects, Dosing

What Is Latuda?

Latuda is a prescription atypical antipsychotic medication used primarily to treat two major mental health conditions: schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression). Unlike many older antipsychotics, Latuda was designed with a specific pharmacological profile that aims to minimize certain side effects while maintaining therapeutic effectiveness.

The medication belongs to the second generation of antipsychotic drugs, often called “atypical” antipsychotics because they work differently than first-generation medications and generally cause fewer movement-related side effects. Latuda is available in tablet form and is taken once daily, making it convenient for patients managing chronic conditions.

How Latuda Works

Mechanism of Action

Latuda works by modulating neurotransmitter activity in the brain, particularly dopamine and serotonin. Its effectiveness stems from its unique binding profile to specific receptor sites:

Dopamine D2 Receptor Antagonism: Latuda blocks dopamine D2 receptors in the brain. Overactivity of dopamine in certain brain pathways is associated with psychotic symptoms like hallucinations and delusions. By moderating this activity, Latuda helps reduce these symptoms.
Serotonin 5-HT2A Receptor Antagonism: The medication also blocks serotonin 5-HT2A receptors. This action is thought to contribute to its antipsychotic effects and may help improve mood symptoms.
Serotonin 5-HT7 Receptor Antagonism: Latuda has high affinity for 5-HT7 receptors, which may contribute to its antidepressant effects, particularly in bipolar depression.
Partial Serotonin 5-HT1A Receptor Agonism: Unlike many antipsychotics, Latuda partially activates 5-HT1A receptors, which may contribute to its favorable side effect profile and cognitive benefits.

Importantly, Latuda has minimal interaction with histamine H1 receptors and muscarinic acetylcholine receptors. This selectivity explains why it causes less sedation and fewer anticholinergic side effects (like dry mouth and constipation) compared to some other antipsychotics.

Pharmacokinetics (How the Body Processes the Drug)

Understanding how Latuda moves through the body helps explain why proper administration is crucial:

Absorption: Latuda is absorbed in the gastrointestinal tract, but absorption is highly dependent on food intake. Taking Latuda with food (at least 350 calories) increases the amount of medication absorbed by approximately 2-fold compared to taking it on an empty stomach. This is why doctors emphasize taking it with a meal.
Peak Concentration: The medication reaches peak blood levels approximately 1-3 hours after ingestion when taken with food.
Protein Binding: About 99% of Latuda in the bloodstream is bound to plasma proteins, meaning only a small fraction is actively circulating.
Metabolism: The liver processes Latuda primarily through the CYP3A4 enzyme pathway. This is important because medications that affect this enzyme can significantly alter Latuda levels in the body.
Elimination Half-Life: The half-life is approximately 18 hours, which supports once-daily dosing.
Excretion: Approximately 80% of the drug is eliminated through feces and 9% through urine.

Latuda Specifications Table

Specification	Details
Generic Name	Lurasidone hydrochloride
Brand Name	Latuda
Drug Class	Atypical antipsychotic (benzisothiazol derivative)
FDA Approval Date	October 28, 2010
Manufacturer	Sumitomo Pharma America, Inc.
Available Strengths	20 mg, 40 mg, 60 mg, 80 mg, 120 mg tablets
Route of Administration	Oral
Frequency	Once daily
Food Requirement	Must take with ≥350 calories of food
Half-Life	Approximately 18 hours
Protein Binding	~99%
Primary Metabolism	Hepatic (CYP3A4)
Excretion	80% feces, 9% urine
Controlled Substance	No
Pregnancy Category	Risk summary available (consult prescribing information)
Storage	Room temperature (68°F-77°F / 20°C-25°C)
Inactive Ingredients	Opadry, magnesium stearate, hypromellose, croscarmellose sodium, pregelatinized starch, mannitol, carnauba wax (80 mg version contains FD&C Blue No. 2 Aluminum Lake and yellow ferric oxide).

FDA-Approved Indications

Latuda is approved for the following conditions:

Schizophrenia (Adults and Adolescents)

Latuda is indicated for treating schizophrenia in adults and adolescents aged 13 to 17 years. Symptoms of schizophrenia typically include hallucinations (hearing or seeing things that aren’t there), delusions (false beliefs), disorganized thinking, and negative symptoms (reduced emotional expression or motivation).

Clinical Evidence: The effectiveness of Latuda for schizophrenia was established in five 6-week controlled studies in adult patients, demonstrating significant improvement in symptoms compared to placebo.

Bipolar I Disorder – Depressive Episodes (Adults and Pediatric Patients)

Latuda is approved for treating major depressive episodes associated with bipolar I disorder in two ways:

As Monotherapy: Used alone to treat depressive episodes in adults and pediatric patients aged 10 to 17 years.
As Adjunctive Therapy: Used in combination with lithium or valproate (mood stabilizers) for adults with bipolar depression.

Important Note: Latuda is specifically approved for the depressive phase of bipolar disorder, not for manic episodes. Its effectiveness in treating mania has not been established.

Clinical Evidence: In controlled studies, Latuda demonstrated superiority over placebo in reducing depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).

Latuda Dosage and Administration Guidelines

Indication	Starting Dose	Recommended Dose Range	Maximum Dose	Special Notes
Schizophrenia (Adults)	40 mg once daily	40-160 mg/day	160 mg/day	No initial titration required
Schizophrenia (Adolescents 13-17)	40 mg once daily	40-80 mg/day	80 mg/day	Pediatric dosing established
Bipolar Depression (Adults)	20 mg once daily	20-120 mg/day	120 mg/day	Effective as monotherapy or adjunctive
Bipolar Depression (Pediatric 10-17)	20 mg once daily	20-80 mg/day	80 mg/day	Approved December 2019
Moderate Renal Impairment	20 mg once daily	20-80 mg/day	80 mg/day	CrCl 30-49 mL/min
Severe Renal Impairment	20 mg once daily	20-80 mg/day	80 mg/day	CrCl <30 mL/min
Moderate Hepatic Impairment	20 mg once daily	20-80 mg/day	80 mg/day	Child-Pugh Score 7-9
Severe Hepatic Impairment	20 mg once daily	20-40 mg/day	40 mg/day	Child-Pugh Score 10-15

Critical Administration Instructions

Take with Food: This cannot be overstated—Latuda must be taken with at least 350 calories of food. Taking it on an empty stomach reduces absorption by approximately 50%, potentially making the medication less effective. A substantial snack or meal is necessary.

Timing: Latuda is typically taken once daily. Many patients prefer taking it with dinner to minimize daytime drowsiness, though it can be taken at any time of day as long as it’s with food.

Missed Doses: If you miss a dose, take it as soon as you remember with food. However, if it’s close to your next scheduled dose, skip the missed dose and take the next one at the regular time. If you missed a dose, do not take missed and new one at the same time.

Side Effects and Adverse Reactions

Understanding potential side effects helps patients and caregivers monitor for issues and communicate effectively with healthcare providers.

Common Side Effects (Occurring in >5% of Patients)

Schizophrenia Studies:

Somnolence/sedation (17.0% vs. 7.1% placebo)
Akathisia (restlessness) (13.5% vs. 3.0% placebo)
Extrapyramidal symptoms (movement disorders) (13.0% vs. 5.2% placebo)
Nausea (10.4% vs. 5.2% placebo)
Parkinsonism (10.0% vs. 2.3% placebo)
Vomiting (7.7% vs. 3.7% placebo)

Bipolar Depression Studies:

Akathisia (11.5% vs. 3.0% placebo)
Extrapyramidal symptoms (8.3% vs. 3.4% placebo)
Somnolence (8.2% vs. 4.2% placebo)
Nausea (7.9% vs. 4.2% placebo)
Diarrhea (6.4% vs. 3.9% placebo)
Anxiety (5.5% vs. 3.9% placebo)

Serious Side Effects Requiring Immediate Medical Attention

Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal condition characterized by high fever, muscle rigidity, altered mental status, and autonomic instability. This requires immediate emergency care.
Tardive Dyskinesia (TD): A movement disorder that may become permanent, involving repetitive, involuntary movements, particularly of the face (lip smacking, tongue protrusion, chewing motions). Early detection is crucial.

Metabolic Changes:

Hyperglycemia/Diabetes: Symptoms include increased thirst, frequent urination, excessive hunger, weakness, fruity breath odor
Dyslipidemia: Abnormal cholesterol or triglyceride levels
Weight Gain: While Latuda has a relatively neutral weight profile compared to some antipsychotics, monitoring is still necessary
Orthostatic Hypotension and Falls: Sudden drops in blood pressure when standing, causing dizziness, lightheadedness, or fainting. This is particularly concerning for elderly patients.
Leukopenia/Neutropenia/Agranulocytosis: Low white blood cell counts that can increase infection risk. Symptoms include fever, sore throat, weakness, or signs of infection.
Seizures: Latuda may lower the seizure threshold.
Suicidal Thoughts and Behaviors: As with all antidepressants and antipsychotics, young adults may experience increased suicidal ideation, particularly when starting treatment or changing doses.
Hyperprolactinemia: Elevated prolactin levels that can cause menstrual irregularities, breast milk production (galactorrhea), sexual dysfunction, or decreased bone density over time.
Body Temperature Dysregulation: Impaired ability to regulate body temperature, particularly in hot weather or during exercise, leading to overheating and dehydration.
Dysphagia: Difficulty swallowing that may increase choking risk, particularly in patients with pre-existing swallowing difficulties.

Black Box Warnings

Antipsychotic medications increase mortality risk in older adults experiencing psychotic symptoms linked to dementia.Latuda is not approved for treating dementia-related psychosis.
Short-term studies show antidepressants heighten suicidal ideation and behavior risk in children, teens, and young adults. All patients starting treatment should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior.

Latuda and Drug Interactions: Critical Information

Latuda’s metabolism through the CYP3A4 pathway makes it susceptible to significant drug interactions. Some combinations are contraindicated (should not be used together), while others require caution.

Contraindicated Interactions (Do Not Use Together)

Strong CYP3A4 Inhibitors: These drugs significantly increase Latuda levels, potentially causing dangerous side effects.

Ketoconazole, itraconazole, voriconazole, posaconazole (antifungals)
Clarithromycin (antibiotic)
Ritonavir, atazanavir (HIV medications)
Grapefruit juice (should be avoided entirely)

Strong CYP3A4 Inducers: These drugs significantly decrease Latuda levels, making it ineffective.

Carbamazepine (anticonvulsant/mood stabilizer)
Phenytoin (anticonvulsant)
Rifampin (antibiotic for tuberculosis)
St. John’s wort (herbal supplement)

Moderate Interactions (Use with Caution)

Moderate CYP3A4 Inhibitors: May require Latuda dose reduction.

Diltiazem, verapamil (calcium channel blockers)
Erythromycin (antibiotic)
Fluconazole (antifungal)

Moderate CYP3A4 Inducers: May reduce Latuda effectiveness.

Bosentan, modafinil, nafcillin

Other Important Interactions

Central Nervous System Depressants: Alcohol, benzodiazepines, opioids, sleep medications, and antihistamines may increase sedation when combined with Latuda. Avoid alcohol entirely.
Antihypertensive Medications: May increase the risk of low blood pressure and dizziness.
Levodopa and Dopamine Agonists: Latuda may antagonize the effects of these Parkinson’s disease medications.
Metoclopramide: Contraindicated due to increased risk of extrapyramidal symptoms.

Special Populations and Precautions

Elderly Patients

Elderly patients with dementia-related psychosis are at increased risk of death when treated with antipsychotics. Latuda is not approved for this use. Additionally, elderly patients are more susceptible to orthostatic hypotension, falls, and sedation.

Pediatric Patients

Latuda is approved for adolescents (13-17 years) with schizophrenia and pediatric patients (10-17 years) with bipolar depression. A 2025 FDA pediatric postmarketing review found no new safety signals in pediatric patients, with no deaths directly associated with lurasidone in this age group.

Pregnancy and Breastfeeding

Pregnancy: Latuda should be used during pregnancy only if the potential benefit justifies the potential risk. Exposure during the third trimester may cause extrapyramidal symptoms or withdrawal symptoms in newborns. Pregnant patients should register with the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388).
Breastfeeding: It is unknown whether Latuda passes into breast milk. The decision to breastfeed should consider the mother’s clinical need for Latuda and potential adverse effects on the breastfed infant.

Renal Impairment

Dose reduction is required for moderate (CrCl 30-49 mL/min) and severe (CrCl <30 mL/min) renal impairment. Begin treatment at 20 mg daily, not exceeding 80 mg per day.

Hepatic Impairment

Dose reduction is required for moderate (Child-Pugh 7-9) and severe (Child-Pugh 10-15) hepatic impairment. Starting dose is 20 mg/day, with maximums of 80 mg/day (moderate) and 40 mg/day (severe).

Patients with Diabetes or Cardiovascular Disease

Latuda should be used cautiously in patients with diabetes, as it may worsen glycemic control. Cardiovascular monitoring is important due to potential orthostatic hypotension and metabolic effects.

What Do You Need To Watch For If You Are Using Latuda

Healthcare providers should ensure patients understand:

Always take with food—a substantial meal or snack containing at least 350 calories
Avoid grapefruit and grapefruit juice entirely during treatment
Do not stop abruptly without consulting your doctor
Report unusual movements immediately (possible tardive dyskinesia)
Monitor for signs of high blood sugar (increased thirst, frequent urination)
Attend all follow-up appointments for monitoring
Seek immediate help for suicidal thoughts or severe side effects
Do not drive or operate machinery until you know how Latuda affects you.

Sources & References

American Psychiatric Association (2022) Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. 5th rev. edn. Washington, DC: American Psychiatric Publishing.
Citrome, L. (2011) ‘Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic’, International Journal of Clinical Practice, 65(2), pp. 189–210.
Citrome, L. (2014) ‘Lurasidone for the treatment of bipolar depression: an evidence-based review’, Neuropsychiatric Disease and Treatment, 10, pp. 49–65.
Loebel, A. et al. (2014) ‘Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study’, American Journal of Psychiatry, 171(2), pp. 160–168.
Mauri, M.C. et al. (2014) ‘Lurasidone: a new atypical antipsychotic for the treatment of schizophrenia and bipolar depression’, Current Drug Targets, 15(2), pp. 159–170.
Sunovion Pharmaceuticals Inc. (2023) Latuda (lurasidone hydrochloride) tablets: prescribing information. Marlborough, MA: Sunovion Pharmaceuticals Inc.
Taku, H. et al. (2019) ‘Pharmacology, efficacy, and safety of lurasidone in the treatment of schizophrenia and bipolar depression’, CNS Drugs, 33(1), pp. 33–51.
Yatham, L.N. et al. (2018) ‘Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder’, Bipolar Disorders, 20(2), pp. 97–170.